Core Viewpoint - Phio Pharmaceuticals is advancing its proprietary INTASYL® gene silencing technology aimed at treating skin cancers, with positive interim results reported from an ongoing Phase 1b clinical trial for its lead compound PH-762 [1][4]. Group 1: Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on immuno-oncology therapeutics [4]. - The company's lead clinical program, PH-762, targets the PD-1 gene associated with various skin cancers, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [4]. Group 2: Clinical Trial Progress - The ongoing Phase 1b dose escalation clinical trial for PH-762 has shown positive interim safety and efficacy results [1]. - PH-762 is being evaluated as a potential non-surgical treatment option for skin cancers [4]. Group 3: Upcoming Events - Phio Pharmaceuticals will participate in a live virtual non-deal roadshow hosted by Renmark Financial Communications on September 30, 2025, where CEO Robert Bitterman will present updates on the company's technology and clinical progress [2][3].

Core Insights - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biotechnology company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology to combat cancer [1][4] - The company announced podium presentations for its lead INTASYL product candidates, PH-762 and PH-894, at the 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany [1] Product Candidates - PH-762 is an INTASYL siRNA compound targeting PD-1, currently undergoing evaluation in an ongoing clinical trial (NCT 06014086) as a neoadjuvant intratumoral therapy for cutaneous malignancies, showing promising preclinical efficacy and favorable tolerability [2][4] - PH-894 selectively silences BRD4, enhancing NK cell activation and proliferation without off-target effects, representing a novel approach to improve adoptive cell therapy [3] Conference Presentations - Melissa Maxwell, Phio's Director of Research and Program Management, will present on PH-762 during the Plenary Session 3, focusing on its preclinical advances and ongoing clinical evaluation [2] - PH-894 will be discussed in Plenary Session 11, highlighting its potential to increase NK cell activity for adoptive cell therapy [3]